Overview Denosumab Adherence Preference Satisfaction Study Status: Completed Trial end date: 2010-06-01 Target enrollment: Participant gender: Summary The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12 months). Phase: Phase 3 Details Lead Sponsor: AmgenTreatments: AlendronateDenosumab